News
Market and company headlines
WATAll
Loading
04:00-09:00Oct 232 Stories
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.
Waters And Labcorp To Expand Access To BD Onclarity HPV Assay
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center,
00:00Oct 211 Story
08:00-10:00Oct 203 Stories
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.
Josh Brown's "Best Stocks in the Market:" Waters and Thermo Fisher
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to spotlight Waters Corporation and Thermo Fisher in his "Best Stocks in the Market."
03:00-10:00Oct 192 Stories
Earnings Preview: What to Expect From Waters Corporation’s Report
Waters Corporation is all geared up to release its third-quarter earnings next month, and analysts anticipate a double-digit boost in its profitability.
Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation
Ultima Genomics, Inc., developer of ultra-high-throughput next-generation sequencing (NGS) platforms, today announced that its recently launched UG200 Sequencing Platform has been selected to power a new large-scale immune profiling study with IMU Biosciences and UK Biobank. The study will generate one of the most detailed pictures of the human immune system assembled to date, adding a high-resolution immune data layer and a foundational dataset for AI to UK Biobank, one of the world's most impo
12:00Oct 151 Story
07:00-09:00Oct 132 Stories
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.
TD Cowen Maintains Buy on Waters, Raises Price Target to $515
TD Cowen analyst Dan Brennan maintains Waters (NYSE:WAT) with a Buy and raises the price target from $475 to $515.
09:00Oct 81 Story
06:00-08:00Oct 72 Stories
Barclays Maintains Overweight on Waters, Raises Price Target to $500
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.
Nvidia, Micron and Other 5 S&P 500 Stocks With +100% Revenue Growth
Micron, Sandisk and Nvidia lead seven S&P 500 stocks that more than doubled quarterly revenue. Six sell AI hardware.
06:00Oct 61 Story
09:00Oct 51 Story
05:00-10:00Oct 12 Stories
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 1, 2026, at midnight Eastern Time.
Guggenheim Maintains Buy on Waters, Raises Price Target to $490
Guggenheim analyst Subbu Nambi maintains Waters (NYSE:WAT) with a Buy and raises the price target from $440 to $490.
15:00Sep 301 Story
19:00Sep 271 Story
08:00-11:00Sep 232 Stories
Waters: Positive Momentum Rides High Again
Waters has rebounded sharply, with shares rising from $300 to $425 on solid organic and acquired sales growth. Click to read more about the WAT stock here.
Robust Results Lifted Waters (WAT)
Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter performance since 2020, driven largely by enthusiasm for Artificial Intelligence. Nine of the ten largest companies in the Russell Midcap Index […]
06:00Sep 231 Story
03:00Sep 211 Story
08:00-11:00Sep 182 Stories
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.
How Is Waters Corporation's Stock Performance Compared to Other Health Care Stocks?
Waters Corporation has outperformed the Health Care industry over the past year, and analysts are moderately optimistic about the stock’s prospects.
06:00Sep 171 Story
06:00-09:00Sep 142 Stories
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation (NYSE: WAT) today announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectral resolution and sensitivity with industry-leading standardization and ease-of-use features, making the power of advanced flow cytometry more accessible to researchers in academia and pharmaceutical settings, as well as in contract research organization (CRO) labs.
$1000 Invested In Waters 20 Years Ago Would Be Worth This Much Today
Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.59% on an annualized basis producing an average annual return of 11.74%. Currently, Waters has a market capitalization of $39.99 billion. Buying
09:00Sep 111 Story
08:00Sep 41 Story
20:00-00:00Sep 32 Stories
Waters (WAT) Raised Guidance, Is The Stock Still Cheap?
Waters (WAT) stock is back in focus after the company reported Q2 2026 adjusted earnings of $3.05 per share and raised its full year guidance for organic revenue growth and adjusted earnings. At a share price of $413.56, Waters has posted a 30 day share price return of 4.41% and a 90 day share price return of 13.19%. The 1 year total shareholder return of 38% and 3 year total shareholder return of 53% point to building momentum supported by upgraded guidance and recent leadership...
Leadership Shift And Upgraded Outlook Could Be A Game Changer For Waters (WAT)
Waters Corporation recently announced that Senior Vice President of the Waters Analytical Sciences Division, Robert L. Carpio III, resigned in August 2026, with Tina Wu, previously head of the Materials Sciences Division and President, China, stepping into the role after more than two decades of global leadership experience at DuPont. Around the same time, Waters reported very large year-over-year revenue growth in the second quarter of 2026 and raised its full-year guidance, underlining the...
11:00Sep 31 Story
04:00-13:00Aug 282 Stories
If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today
Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.82% on an annualized basis producing an average annual return of 12.05%. Currently, Waters has a market capitalization of $41.46 billion. Buying
Is Wall Street Bullish or Bearish on Waters Corporation Stock?
Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
08:00-10:00Aug 272 Stories
This Waters Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
Top Wall Street analysts upgraded BWX Technologies, The Macerich Company, and Waters Corporation. Check out analyst ratings and price targets.
Piper Sandler Upgrades Waters to Overweight, Raises Price Target to $480
Piper Sandler analyst David Westenberg upgrades Waters (NYSE:WAT) from Neutral to Overweight and raises the price target from $400 to $480.
10:00-16:00Aug 262 Stories
Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.
Waters Corporation to Present at the Wells Fargo Healthcare Conference
Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10:15 AM Eastern Time.
11:00Aug 241 Story
11:00Aug 211 Story
07:00Aug 181 Story
21:00Aug 121 Story
12:00Aug 111 Story
06:00-15:00Aug 102 Stories
1 Surging Stock with Competitive Advantages and 2 We Turn Down
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Citigroup Maintains Buy on Waters, Raises Price Target to $470
Citigroup analyst Joanne Wuensch maintains Waters (NYSE:WAT) with a Buy and raises the price target from $425 to $470.